home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

ALK

SHARESHARESHARE
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy.
SHARESHARESHARE

RELATED NEWS


Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examinat...
GLOBENEWSWIRE
READ MORE

Commercial launch readiness is a critical stage in a product life cycle. While the world hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will only increase price pressures overall for the industry. The era of increasing competitive and price pressure is not going away and capturing full value from every product launch is critical. However, history shows that only a third of product launches meet analyst expectations. Teams with the ability to opt...
PRWEB
READ MORE

COVID-19 swiftly changed the healthcare landscape around the world. There has been no rulebook for pharmaceutical commercialization during COVID-19. Pharmaceutical commercialization teams have had to quickly adapt to meet customer, community and business needs. Remote customer engagement and increased patient support services were the answer in the short term for pharmaceutical commercialization amid COVID-19. Longer term, teams will need to adapt brand strategy and executional approaches for in...
PRWEB
READ MORE

Gilead Sciences can only produce so much of its newly authorized COVID-19 drug remdesivir, so it’s scouting other companies to bolster global supply. Even as it presses ahead with its own remdesivir ramp-up, Gilead says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022. Remdesivir manufacturing relies on “s...
FIERCEPHARMA
READ MORE

The decision was based on Phase 3 comparing Alunbrig to crizotinib in the same indication. The findings for Alunbrig showed a 69% reduction in risk of intracranial disease progression or death in patients with brain metastases according to a blinded independent review committee, and a 76% reduction according to investigators. The drug also demonstrated a median progression-free survival of 24 months, more than double the 11 months presented by crizotinib. Because of the complex nature of ALK+ NS...

READ MORE

Money talks in Washington, D.C., and no sector of the economy speaks more loudly than the pharmaceutical and biotech industry. Its flow of cash has fostered an epidemic of medication overload. Over the past five years, pharma has spent about $1.2 billion lobbying federal lawmakers, far more than any other industry. The industry has massive influence over public policy, much of it devoted in recent months to hindering legislative efforts to lower drug prices. In addition to keeping prices high, t...

READ MORE

Pfizer aims to be the third big pharma with a significant presence in gene therapy. Its plans to initiate this year three Phase 3 trials targeting mutation-driven blood and muscular diseases would make it a large player in this cutting-edge area of medicine. The difference between Pfizer and its Swiss rivals Novartis and Roche is that its treatments for muscular dystrophy and hemophilia do not look like they will be the first to market. With hopes that gene therapy could be a one-and-done treatm...

READ MORE

95Visual is pleased to announce the launch of Blue River Pharmacy’s new website. The primary goal during the process was to improve the navigation of Blue River’s vast product offering. Specifically, Blue River wanted an exceptionally organized website with easy-to-read text for all patients and customers. The features Blue River chose to include in the redesign now make finding products a breeze. Customers will love how Blue River goes above and beyond to ensure they provide the bes...

READ MORE

In the year ahead, health care promises to be a central issue in the 2020 election. According to a report issued this week at the 2o19 American Society of Health System Pharmacists Midyear Clinical Meeting & Exposition  from McKesson RxO, which detailed the major trends and challenges in health care ahead, the increasing complexity of integrated delivery networks and a need for more technology and associated analytics were highlighted as major areas of focus in the year ahead and in fut...

READ MORE

The US Food and Drug Administration (FDA) has approved Biogen and Alkermes’ oral drug Vumerity (diroximel fumarate) to treat relapsing forms of multiple sclerosis (MS). Biogen holds the exclusive licence to commercialise the drug globally and intends to make it available in the US in the coming days. Biogen chief medical officer and research and development executive vice-president Alfred Sandrock said: “The FDA’s approval of Vumerity delivers on Biogen’s commitment to pu...

READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...